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LETTER TO THE EDITOR
RE: Talks BJ, Fernquest S, Palmer A, et al. 2019. No Evidence of Systemic
Inflammation in Symptomatic Patients With Femoroacetabular Impingement
Dear Professor Sandell,
We are writing in regards to an article by Talks et al.1
that was recently published in the Journal of Ortho-
paedic Research. The stated aim of the study was to
“determine whether there was evidence of systemic in-
flammation in patients with femoroacetabular impinge-
ment (FAI), defined by serum‐free light chains (sFLCs),
and whether this correlated with markers of disease se-
verity.” The article measured sFLCs in 115 patients with
FAI, with 57 patients undergoing surgical intervention
and 58 receiving physiotherapy. The authors did not in-
clude a cohort of demographically matched athletes that
do not have FAI. The study found that the baseline levels
of sFLCs in all patients was 30.36± 9.23mg/l, and at
follow‐up, the levels in the surgical intervention was
29.48± 7.85 and 31.68± 9.61mg/l. On the basis of no
observed change in sFLC levels in response to surgical or
conservative interventions, the authors concluded that
no systemic inflammation was present in patients
with FAI.
We would like to acknowledge the authors on per-
forming a biomarkers study in 115 patients with FAI. The
sample size is impressive, and we need more well‐powered
studies with diverse patient populations. We also appre-
ciate the importance of identifying factors that can help in
predicting appropriate candidates for surgical versus con-
servative treatment. The data in this paper that showed
an improvement in patient‐reported outcomes in surgical
but not conservative treated patients is an important
contribution to the FAI literature. We do, however, have
concerns about conclusions the authors made regarding
inflammation and FAI.
A previous study from our lab in athletes with FAI
demonstrated that, compared to age‐ and activity‐matched
athletes without FAI, those with FAI had a 24% increase
in mean circulating levels of cartilage oligomeric matrix
protein (COMP) and a nearly threefold elevation in mean
circulating levels of C‐reactive protein (CRP).2 COMP has
been used as a marker of cartilage turnover in patients
with osteoarthritis (OA), and CRP has been used as a
marker of inflammation in OA and many other chronic
conditions.3 Additionally, biopsies of tissue from patients
undergoing FAI corrective surgery have shown clear signs
of local inflammation in the hip joint.4–6 While there was a
fair amount of variability in CRP levels in our study,
and we only had N=19 subjects in the control and
N=10 in the FAI cohort, given the evidence of local
inflammation in FAI and OA, and studies demonstrating
systemic inflammation in patients with OA, we do think
inflammation likely plays a role in symptoms associated
with FAI.
The topic of inflammation in FAI is important in
understanding the etiology and treatment options for
the condition, but we do not think the paper by Talks
et al. measure a clinically meaningful marker of in-
flammation in an athletic population. sFLCs are pro-
duced by activated plasma cells, and are commonly
used in the diagnosis and monitoring of multiple mye-
loma.7 As the authors point out, there are some in-
dications that sFLCs can be useful in monitoring
rheumatoid arthritis (RA), but no studies have eval-
uated sFLCs in OA. Outside of multiple myeloma and
RA, other studies in the literature that use sFLCs to
monitor disease progression focus on various other
cancers and severe systemic diseases. For these con-
ditions, there is a clear suspected role for a plasma cell
response in the disease pathology. Elias‐Jones et al.6
evaluated the presence of various immune cell pop-
ulations in patients with FAI and observed virtually no
CD3+ T‐lymphocytes in labral biopsies, although a ro-
bust innate immune response was present. On the
basis of the lack of an adaptive immune cell presence in
patients with FAI, and general observations of the
adaptive immune system in other musculoskeletal in-
juries and diseases, we would not anticipate plasma
cells to be activated at a substantial level in the case of
otherwise healthy athletes with FAI.
Since there is no evidence that sFLCs are useful bio-
markers of inflammation outside of autoimmune disease
or severe systemic diseases, the available data does not
support Talks et al. rejection of inflammation in FAI.
Furthermore, an absence of a reduction in sFLCs after
surgical intervention is not synonymous with the absence
of baseline inflammation. Although we continue to un-
derstand the pathophysiology of hip impingement, based
on the best available evidence we hold that reducing in-
flammation should continue to be a clinical objective in the
treatment of patients with FAI.
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